Efficacy and safety of perioperative chemotherapy with 5FU-cisplatine-cetuximab in gastric and gastroesophageal junction adenocarcinomas (GGOJA): A single-arm multicenter phase II trial (FFCD 0901).

Authors

Christophe Mariette

Department of Digestive and Oncologic Surgery, Claude Huriez University Hospital, Lille, France

Christophe Mariette , Guillaume Piessen , Carole Monterymard , Denis Pezet , Aurelie Ferru , Mathieu Baconnier , Xavier Adhoute , David Tavan , Olivier Bouche

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trials of cetuximab plus combined modality therapy (CMT) in squamous cell carcinoma of the anal canal (SCCAC) with and without human immunodeficiency virus (HIV) infection.

First Author: Madhur Garg

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.

First Author: Erminia Massarelli

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.

First Author: Ralf Hofheinz

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX).

First Author: L. Dahan